Deutsch | English | Español | Français | Italiano | Português | Русский | العربية | 日本語 | 简体中文 | 繁體中文 | 한국의 | Türk | Polski
LOGO
Global B2B Portal for Bio-Medical & Pharm Industry
Product / Service Supplier Catalogs & Literature    
Search
or
home Product News Catalogs Web TV News & Topics Featured Articles Trade Shows Sourcing Help My allbiomedical
Keyword for News & Topics:
Market News, Trends and Topics
E-mail to Colleague Print
Vaccine made with synthetic gene protects against deadly pneumonia 2011-02-23
Author: EurekAlert
From: Bioscience Technology
Researchers at Albert Einstein College of Medicine of Yeshiva University have developed an experimental vaccine that appears to protect against an increasingly common and particularly deadly form of pneumococcal pneumonia. Details of the new vaccine, which was tested in an animal model, are reported
Hyperlink to Original Source

Oseltamivir oral suspension back-ordered due to increased demand 2011-02-22
Author: Drug Topics Staff
From: Drug Topics
Oseltamivir phosphate oral suspension (Tamiflu) is on back order because of increased demand, manufacturer Genentech announced. However, supplies are not yet depleted at wholesalers and pharmacies.
Hyperlink to Original Source

FDA approves drug to prevent premature births 2011-02-22
Author: Drug Topics Staff
From: Drug Topics
FDA has approved hydroxyprogesterone caproate injection (Makena [formerly named Gestiva]; Hologic and KV Pharmaceutical Co.), commonly referred to as “17P,” the first drug to help prevent premature delivery before 37 weeks in women who have had at least 1 previous preterm birth.
Hyperlink to Original Source

Forest Acquiring Clinical Data for $1.2B 2011-02-22
Author: Drug Discovery & Development Staff
From: Drug Discovery & Development
Forest Laboratories Inc. said it is buying specialty pharmaceutical company Clinical Data Inc. in a $1.2 billion deal in order to gain access to a key antidepressant. Forest is paying $30 per share, a discount of nearly 12 percent from Clinical Data's closing price on Friday. Forest also will pay an
Hyperlink to Original Source

ACIP revises adult immunization schedule for 2011 2011-02-17
Author: Drug Topics Staff
From: Drug Topics
The Advisory Committee on Immunization Practices (ACIP) announces several changes to the recommended adult immunization schedule for 2011.
Hyperlink to Original Source

UT researchers link algae to harmful estrogen-like compound in water 2011-02-16
Author: EurekAlert
From: Bioscience Technology
University of Tennessee, Knoxville, researchers have found that blue-green algae may be responsible for producing an estrogen-like compound in the environment which could disrupt the normal activity of reproductive hormones and adversely affect fish, plants and human health.
Hyperlink to Original Source

Red Wine Compound Increases Rapamycin Effectiveness 2011-02-15
Author: Drug Discovery & Development Staff
From: Drug Discovery & Development
Researchers from Cleveland Clinic's Lerner Research Institute have discovered that resveratrol – a compound found in red wine – when combined with rapamycin can have a tumor-suppressing effect on breast cancer cells that are resistant to rapamycin alone.
Hyperlink to Original Source

Shire Profits Drop On Costs 2011-02-11
Author: Drug Discovery & Development Staff
From: Drug Discovery & Development
Irish drug developer Shire Plc. said its fourth-quarter profit fell on higher costs, but the results met Wall Street expectations. The company earned $165.1 million, or 88 cents per American Depository Share, down from $174.3 million, or 94 cents per ADS. Revenue rose 4 percent to $931.2 million fro
Hyperlink to Original Source

FDA approves new dose of sodium fluoride for bone scans 2011-02-11
Author: Drug Topics Staff
From: Drug Topics
After its withdrawal from the marketplace 35 years ago, sodium fluoride F 18 for use in bone scans is experiencing a rebirth as a result of a New Drug Application (NDA) submitted by the National Cancer Institute (NCI) and approved by FDA.
Hyperlink to Original Source

Sanofi Profits Plummet 64% in Q4 2011-02-10
Author: Drug Discovery & Development Staff
From: Drug Discovery & Development
Sanofi-Aventis said that hefty new restructuring costs caused its net profit to slump 64 percent in the fourth quarter, amid continued uncertainty over the fate of its nearly $20 billion bid for U.S. biotechnology firm Genzyme Corp.
Hyperlink to Original Source

Note: The copyright and the ownship of the brand, product names, product numbers, and content mentioned belongs to their repective companies.
e-Newsletter
Update your allbiomedical products information to keep ahead with market trend.
Archive
Subscribe Now!!
View by Categories

Chemical and Material

Contract Manufacturing Services

Cosmetics and Beauty Supplies

Dental Products

Electromedical Diagnostics Equipment

Healthcare Products and Nutritional Supplement

Hospital, Lab and Clean Room Equipment

In-vitro Diagnostics

Manufacturing Equipment

Medical and Surgery Supplies

Medical Imaging

Medical Instrument Components

Medical IT

Medicine, Vaccine and Drug Delivery Systems

Packaging, Labelling, Printing, Barcoding

Pharmaceutical Machinery

Physiotherapy/Orthopaedic Equipment

Services for Medical Industry

Surgery and Endoscopy

Therapy and Physical Medical Devices
My Allbiomedical
Take advantage of the benefits of My %%webname%%
- Track your sourcing projects
- View your search history
- Create a contact list
- Get latest new products and suppliers
- Send inquiries direct to suppliers
- Submit press release, and download detailed suppliers profiles, product profiles, and CAD drawing

Sign-up FREE Now
Featured Articles
Featured Pages
Contents
· Home
· Product News
· Catalogs
· Web TV
· News & Topics
· Features Articles
· Trade Show
· Sourcing Help
· My Allbiomedical
Special Zone
· Directory
· Trade Show Supplement
Allbiomedical.com
· About Us
· Promote Your Business
· Advertise
· Partner with Us
· Press Release
· Contact Us
· Term of Use
· Privacy Policy
· Starter Program
· Sitemap
B2B Web Portal Alliance
· Allitwares.com
· Allmetalworking.com
· Allbiomedical.com
· Allautowares.com
Buy Engineer Sample Kits
OEM Sourcing
Language
· Deutsch
· English
· Español
· Français
· Italiano
· Português
· Русский
· العربية
· 日本語
· 简体中文
· 繁體中文
· 한국의
· Türk
· Polski
 
   

Copyrights © 2012 Allitwares Corporation All Rights Reserved. www.allbiomedical.com is a Division of Allitwares Corporation
www.allbiomedical.com is a B2B Trade Portal | B2B Web Portal |B2B Marketplace for biomedical and pharmaceutical industry